Rhumbline Advisers Has $546,000 Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Rhumbline Advisers increased its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 51,270 shares of the company’s stock after purchasing an additional 1,402 shares during the quarter. Rhumbline Advisers owned approximately 0.22% of UroGen Pharma worth $546,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its stake in UroGen Pharma by 44.1% in the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock valued at $216,000 after acquiring an additional 6,207 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in UroGen Pharma by 263.1% in the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock valued at $864,000 after acquiring an additional 49,318 shares during the last quarter. Tidal Investments LLC lifted its stake in UroGen Pharma by 19.1% in the third quarter. Tidal Investments LLC now owns 37,595 shares of the company’s stock valued at $477,000 after acquiring an additional 6,030 shares during the last quarter. Barclays PLC lifted its stake in UroGen Pharma by 409.3% in the third quarter. Barclays PLC now owns 59,778 shares of the company’s stock valued at $759,000 after acquiring an additional 48,040 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in UroGen Pharma by 8.1% in the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after acquiring an additional 34,248 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Price Performance

Shares of UroGen Pharma stock opened at $9.82 on Friday. The firm has a fifty day simple moving average of $10.45 and a 200-day simple moving average of $11.78. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma Ltd. has a 1-year low of $9.03 and a 1-year high of $20.70. The stock has a market capitalization of $230.32 million, a price-to-earnings ratio of -3.12 and a beta of 1.12.

Insider Buying and Selling

In other news, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on URGN shares. HC Wainwright reiterated a “buy” rating and issued a $64.00 target price on shares of UroGen Pharma in a research note on Tuesday, February 25th. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a research note on Tuesday, February 18th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, UroGen Pharma presently has an average rating of “Buy” and an average target price of $40.00.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.